SaaS entity

Skye Bioscience

Company SKYE

Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention AI Weapons Detection, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.6 for the broader beat in this window.

Last mentioned: Mar 9, 2026

Entity pulse

Recent coverage · Skye Bioscience

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Skye Bioscience

Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention AI Weapons Detection, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.2 for that window. Skye Bioscience appears in 1 tracked SaaS story from March 9, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 35 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Skye Bioscience. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Expected Earnings Call

    Management is expected to discuss financial results and 2026 guidance with analysts.

  2. Earnings Preview Released

    Seeking Alpha publishes earnings previews for Evolv Technologies and Skye Bioscience.

  3. Q4 Fiscal Period Ends

    Evolv Technologies concludes its fourth quarter of the 2025 fiscal year.

Stories mentioning Skye Bioscience 1

Earnings Neutral

Evolv Technologies Q4 2025 Preview: AI Security Growth Under Scrutiny

Evolv Technologies is set to report its fourth-quarter 2025 results, with investors focusing on the company's subscription-based revenue growth and AI-driven screening adoption. The report comes amid a broader push for modernized physical security infrastructure across schools, stadiums, and public venues.

2 sources

Skye Bioscience is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.